Rachel S. Leibman
AbbVie (United States)(US)
Publications by Year
Research Areas
CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Immune Cell Function and Interaction, Immunotherapy and Immune Responses
Most-Cited Works
- → Enterococcus faecalis Produces Abundant Extracellular Structures Containing DNA in the Absence of Cell Lysis during Early Biofilm Formation(2012)158 cited
- → Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor(2017)130 cited
- → Antimicrobial peptides trigger a division block in Escherichia coli through stimulation of a signalling system(2016)71 cited
- → Engineering T Cells to Functionally Cure HIV-1 Infection(2015)52 cited
- → HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo(2020)46 cited
- → First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors(2024)9 cited
- → First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC(2024)7 cited
- → 770 Safety, efficacy, and pharmacokinetic results from a phase I first-in-human study of ABBV-151 with or without anti-PD1 mAb (budigalimab) in patients with locally advanced or metastatic solid tumors(2022)5 cited
- → Abstract CT207: Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors(2021)3 cited
- → 1076TiP First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors(2023)2 cited